Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Watt

Showing results (151-160 of 214) with videos related to

Pageof 22
Sort By:
The Journal of Infectious Diseases|June 26, 2003
Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adultsAndrea L Benin, Katherine L O'Brien, James P Watt, et al.
The Journal of Pediatrics|June 19, 2013
Impact of Haemophilus influenzae Type b conjugate vaccine in Mongolia: prospective population-based surveillance, 2002-2010Susana Scott, Dorjpurev Altanseseg, Demberelsuren Sodbayer, et al.
Journal of Medicinal Chemistry|May 12, 1995
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptorsL J Street, R Baker, W B Davey, et al.
Vaccine|December 30, 2022
Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022 influenza seasonKristin L Andrejko, Jennifer F Myers, John Openshaw, et al.
Journal of Medicinal Chemistry|March 18, 1994
High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing groupG A Showell, S Bourrain, J G Neduvelil, et al.
Cancer Research|October 5, 2001
BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progressionG C Sellar, L Li, K P Watt, et al.
Journal of Medicinal Chemistry|October 24, 2023
Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory DisordersDavid Harrison, Andy Billinton, Mark G Bock, et al.
Journal of Medicinal Chemistry|November 14, 1997
Selective, orally active 5-HT1D receptor agonists as potential antimigraine agentsA M MacLeod, L J Street, A J Reeve, et al.
Plos One|March 8, 2016
Cirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central ObesityJingjing Jiao, Gordon P Watt, MinJae Lee, et al.
Journal of Osteoporosis|June 5, 2018
Glycemic Control and Bone Turnover in Older Mexican Americans with Type 2 DiabetesNahid J Rianon, Scott M Smith, MinJae Lee, et al.
Pageof 22

Showing results (151-160 of 214) with videos related to

Sort By:
Pageof 22
The Journal of Infectious Diseases|June 26, 2003
Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adultsAndrea L Benin, Katherine L O'Brien, James P Watt, et al.
The Journal of Pediatrics|June 19, 2013
Impact of Haemophilus influenzae Type b conjugate vaccine in Mongolia: prospective population-based surveillance, 2002-2010Susana Scott, Dorjpurev Altanseseg, Demberelsuren Sodbayer, et al.
Journal of Medicinal Chemistry|May 12, 1995
Synthesis and serotonergic activity of N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and analogues: potent agonists for 5-HT1D receptorsL J Street, R Baker, W B Davey, et al.
Vaccine|December 30, 2022
Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022 influenza seasonKristin L Andrejko, Jennifer F Myers, John Openshaw, et al.
Journal of Medicinal Chemistry|March 18, 1994
High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing groupG A Showell, S Bourrain, J G Neduvelil, et al.
Cancer Research|October 5, 2001
BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progressionG C Sellar, L Li, K P Watt, et al.
Journal of Medicinal Chemistry|October 24, 2023
Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory DisordersDavid Harrison, Andy Billinton, Mark G Bock, et al.
Journal of Medicinal Chemistry|November 14, 1997
Selective, orally active 5-HT1D receptor agonists as potential antimigraine agentsA M MacLeod, L J Street, A J Reeve, et al.
Plos One|March 8, 2016
Cirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central ObesityJingjing Jiao, Gordon P Watt, MinJae Lee, et al.
Journal of Osteoporosis|June 5, 2018
Glycemic Control and Bone Turnover in Older Mexican Americans with Type 2 DiabetesNahid J Rianon, Scott M Smith, MinJae Lee, et al.
Pageof 22